This study is testing if metformin, a common diabetes medication, can be a practical treatment for people with pseudomyxoma peritonei (PMP). PMP is a rare cancer that often starts in the appendix (appendiceal mucinous neoplasms or AMNs). You might be able to join if you have PMP from AMNs that has come back, can't be removed by surgery, or if surgery isn't planned. The main goal is to see if participants can take at least 80% of their planned metformin doses for 6 months. This is a pilot study, meaning it's a small first step to see if this treatment is feasible. The study is currently unclear about its recruitment status and plans to enroll 15 participants.

Study design

This is a single-arm, open-label pilot study, meaning all 15 participants will receive metformin. It's designed to see if metformin treatment is feasible.

What's involved

You would take metformin by mouth for up to 18 months, or until you can no longer tolerate the treatment.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is measured at 6 months, but treatment can continue for up to 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.